Neurelis, Inc.

Particle Sciences, Inc.

Kalvista Pharmaceuticals Limited

Besins Healthcare Luxembourg Sarl

Hale Biopharma Ventures, LLC

Sanofi-topaz, Inc.

Other

Arbor Pharmaceuticals, LLC

Cetylite Industries, Inc.

Garry Thomas Gwozdz

Mark Mitchnick

Edward T Maggio

Steve Cartt

David F Hale

David Medeiros

Andrew L Loxley

Nicholas Spring

Andrew Loxley

Gary Paul Cook

David Fairhurst

Maynard Emanuel Lichty

Theodore Patrick Laslo

Jeffrey Scott Larson

Stephen Horrigan

Roger D Harrison

Steven David Dykstra

Theodore Laslo

Jonathan Northrup

Henry Havel

Abhijit Gokhale

David Hale

The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.

Administration of benzodiazepine compositions

Formulations of tegavivint and related compounds, methods of making such formulations and methods of treating various conditions utilizing such formulations.

Formulations of tegavivint and related compounds

An avermectin-based topical formulation is disclosed which is useful for prevention and treatment of head lice (). This topical formulation may be formulated as a shampoo-condition which comprises an effective amount of avermectin, solubilizers, suspending agents, preservatives, nonionic surfactants, humectants, a silicone compound, and water. Also disclosed are methods of using the topical formulations disclosed within this specification to treat either a susceptible or treatment-resistant strain of lice, as well as uses in the manufacture of a medicament for treating or preventing a lice infestation from a susceptible or treatment-resistant strain in a human patient.

Topical avermectin formulations and methods for elimination and prophylaxis of susceptible and treatment resistant strains of head lice

Provided herein are dry pharmaceutical compositions for transmucosal delivery, comprising spray-dried particles that include pharmaceutically active agent nanoparticles, a binder, and a pharmaceutically acceptable carrier, where the active agent nanoparticles have an average particle size diameter prior to spray-drying of less than about 1 &#x3bc;m, and wherein up to 10% of the spray-dried particles have a particle size of less than 10 &#x3bc;m; at least 50% of the spray-dried particles have a particle size of at least about 15 &#x3bc;m; and at least 90% of the spray-dried particles have a particle size of up to about 55 &#x3bc;m. Also provided are methods for making such pharmaceutical compositions and therapeutic methods comprising transmucosally aministering the compositions, such as intranasally or intravaginally.

Spray-dried pharmaceutical compositions comprising active agent nanoparticles

A targeted drug delivery complex containing a particle, a targeting moiety electrostatically attached to the particle, and an active pharmaceutical ingredient attached to or dispersed or dissolved within the particle is provided. Also provided are pharmaceutical formulations containing a plurality of the complexes as well as methods for use in targeting an active pharmaceutical ingredient to a selected cell or tissue and production of such formulations.

Drug delivery particle formulations with targeting moieties

Provided herein are dry pharmaceutical compositions for transmucosal delivery, comprising spray-dried particles that include pharmaceutically active agent nanoparticles, a binder, and a pharmaceutically acceptable carrier, where the active agent nanoparticles have an average particle size diameter prior to spray-drying of less than about 1 &#x3bc;m, and wherein up to 10% of the spray-dried particles have a particle size of less than 10 &#x3bc;m; at least 50% of the spray-dried particles have a particle size of at least about 15 &#x3bc;m; and at least 90% of the spray-dried particles have a particle size of up to about 55 &#x3bc;m. Also provided are methods for making such pharmaceutical compositions and therapeutic methods comprising transmucosally administering the compositions, such as intranasally or intravaginally.

The invention relates to aqueous suspension pharmaceutical compositions of poorly water soluble drugs, wherein said drugs are selected from compounds of formula I wherein R-Rare defined herein; processes for preparing these compositions and their use in medicine, especially their use in the treatment of ocular diseases.

Pharmaceutical compositions

Delivery devices of a degradable or nondegradable biocompatible matrix with one or more encapsulated active pharmaceutical ingredients or one or more particle-bound active pharmaceutical ingredients dispersed in the matrix are provided. Also provided are methods for delivering an active pharmaceutical ingredient to a subject with these delivery devices. Modified vaginal rings are also provided as well as surface coatings for delivery devices which minimize bio-interaction of the coated delivery devices.

Delivery devices containing encapsulated and/or practice-bound active pharmaceutical ingredients

A topical anesthetic composition comprising benzocaine, pharmaceutically acceptable salt thereof, amide thereof and/or ester thereof; tetracaine and/or pharmaceutically acceptable salt thereof; ethanol; polyethylene glycol; propylene glycol; water; and benzyl alcohol is provided. Also provided is method for dispensing the above topical anesthetic composition to a desired site such by spraying the topical anesthetic from a pump actuated metered dose spray device. The topical anesthetic composition can also be administered subgingivally with a syringe and applicator tip. A product comprising the above topical anesthetic spray composition contained in a pump actuated metered dose spray device.

Topical anesthetic composition

The invention relates to aqueous suspension pharmaceutical compositions of poorly water soluble drugs, wherein said drugs are selected from compounds of formula (I) (Formula (I)), wherein R-Rare defined herein; processes for preparing these compositions and their use in medicine, especially their use in the treatment of ocular diseases. 

Pharmaceutical compositions suitable for parenteral administration comprising aqueous suspensions of benzylamine derivatives having low solubilities

Growing community of inventors

Jim Thorpe, PA, United States of America

Garry Thomas Gwozdz